공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

반코마이신 내성 장내구균 감염증 : 파이프라인 리뷰

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 264091
페이지 정보 영문 102 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


반코마이신 내성 장내구균 감염증 : 파이프라인 리뷰 Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 102 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

반코마이신 내성 장내구균은 VRE이라고 불리며, 원내감염의 원인이 되고 있습니다. 증상은 감염 부위에 따라 다릅니다. 박테리아는 일반적으로 장, 창상, 요로를 통해 감염됩니다. 창상 감염의 경우에는 빨개지고 압통이 있으며, 부종이 나타납니다. 요로 감염의 경우는 허리 통증, 배뇨시 작열감이 발생합니다. 그 밖에 오심, 발열, 오한, 심한 두통, 설사 등의 증상이 나타납니다. 예방을 위해서는 효과적인 위생 실천이 필수적입니다.

반코마이신 내성 장내구균 감염증(Vancomycin-Resistant Enterococcus faecium Infections) 치료제 개발 상황에 대해 조사 분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

서론

  • 조사 범위

반코마이신 내성 장내구균 감염증 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관별 파이프라인
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • Alchemia Ltd
  • Aphios Corp
  • C3J Therapeutics Inc
  • Helix BioMedix Inc
  • Hsiri Therapeutics LLC
  • LegoChem Biosciences Inc
  • Lytix Biopharma AS
  • MGB Biopharma Ltd
  • MicuRx Pharmaceuticals Inc
  • Nanotherapeutics Inc
  • NovoBiotic Pharmaceuticals LLC
  • Oragenics Inc
  • Ovensa Inc
  • Sealife PHARMA GMBH
  • Wockhardt Ltd

약제 개요

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSM 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AimMax Therapeutics Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AnyGen Co Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by LegoChem Biosciences Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic Pharmaceuticals LLC, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sano Chemicals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2021
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, 2021 (Contd..1)
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2021, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 13 and 9 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Vancomycin-Resistant Enterococcus faecium Infections - Overview
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Development
  • Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment
  • Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics Development
  • Vancomycin-Resistant Enterococcus faecium Infections - Drug Profiles
  • Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects
  • Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products
  • Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q